Headshot of Fred Poordad, MD

Fred Poordad, MD

UT Health San Antonio
Schedule an appointment: 210-567-5777
Loading...
Loading...

Overview

Practice Locations

Insurance

Video

Articles & Publications

Specialty

  • Hepatología de trasplantes

Board Affiliation/Certification

  • American Board of Internal Medicine/Gastroenterology
  • American Board of Internal Medicine/Transplant Hepatology

Education

  • University of Alberta (1990)

Residency

  • Medicina Interna, St Thomas Hospital and Medical Center (1993)

Fellowships

  • Gastroenterología, University of South Carolina (1995)
  • Medicina/Gastroenterología-Hepatología, Johns Hopkins Bayview Medical Center - GME (1996)

Languages

  • Inglés

Gender

  • Male

Corpus Christi Specialties

1521 South Staples Street
Suite 402
Corpus Christi,TX 78404
(361) 299-0428
Location Details

Texas Liver Tumor Center

4502 Medical Drive
Transplant Clinic, Rio Tower, Level 2
San Antonio,TX 78229
210-743-4306
Location Details

University Hospital

4502 Medical Drive
San Antonio,TX 78229
210-358-4000
Location Details

Insurance Accepted

  • 6 Degrees - Trasplantes
  • 90 Degree Benefits - Administrador externo
  • Aetna Better Health - CHIP/CHIP Perinatal para recién nacidos
  • Aetna Better Health - Medicaid STAR
  • Aetna Health - Comercial (Choice POS II, Elect Choice EPO, Exchange (Silver/Gold HMO))
  • Aetna Health - Comercial (HMO, Managed Choice POS, Meritain, Open Choice PPO)
  • Aetna Health - Comercial (QPOS, SAISD, Select)
  • Aetna Health - Medicaid Dual Preferred (HMO D-SNP)
  • Aetna Health - Medicare Advantage (Eagle PPO, Freedom PPO, Premier HMO, Prime HMO, Value Plus PPO)
  • Aetna Health - SOLO trasplantes
  • Allegiance - Universal Benefits Consortium
  • Allwell (Superior HealthPlan) - Medicare Advantage
  • Ancira Enterprises - Empleador directo
  • Benefit Administrative Systems - Administrador externo
  • BlueCross BlueShield (Programas federales) - Comercial (Federal - Todos los productos)
  • BlueCross BlueShield (Fuera del estado) - Comercial (Fuera del estado - Solo programa Blue Card)
  • BlueCross BlueShield of Texas - Comercial (Blue Premier HMO, Blue Choice PPO)
  • BlueCross BlueShield of Texas - Comercial (CHIP, Blue Advantage HMO, Blue Essentials HMO)
  • BlueCross BlueShield of Texas - Comercial (ERS, TRS, Empleados del estado de Texas)
  • BlueCross BlueShield of Texas - HPN/EPO (Red Narrow)
  • BlueCross BlueShield of Texas - Medicaid (STAR, STAR Kids, STAR PLUS)
  • BlueCross BlueShield of Texas - Medicare Advantage (HMO, PPO)
  • BlueCross BlueShield of Texas - Planes de doble elegibilidad para Medicare y Medicaid
  • BlueCross BlueShield of Texas - Red tradicional/par
  • BlueCross BlueShield of Texas - Red de trasplantes
  • CHAMPVA - Gubernamental
  • Cigna - Red específica del empleador (United Benefits Consortium)
  • Cigna - Red específica del empleador (solo empleados & dependientes de USAA)
  • Cigna Health Spring - Medicare Advantage (WellMed)
  • Community First Health Plans - CHIP/CHIP Perinatal para recién nacidos
  • Community First Health Plans - Comercial (HMO, Exchange)
  • Community First Health Plans - Medicaid (STAR, STAR Kids, STAR PLUS)
  • Community First Health Plans - Medicare Advantage (HMO)
  • Community First Health Plans - University Family Care Plan
  • Curative - Comercial (Todos los productos)
  • Driscoll Health Plan - Medicaid (Todos los productos)
  • EBSO Benefits - Administrador externo
  • El Paso Health - CHIP
  • El Paso Health - Medicaid STAR
  • Employers Health Network - Comercial (PPO)
  • Entrust - Administrador externo
  • First Health - Comercial (Todos los productos)
  • Gilsbar - Administrador externo
  • HealthSmart (Accel) - Comercial (Todos los productos)
  • Humana - Medicare Advantage (HMO, PPO, WellMed)
  • Humana - Red de trasplantes
  • Imagine 360 - Administrador externo
  • Imperial Health - Comercial (Exchange)
  • Imperial Health Plan - Medicare Advantage
  • Independent Medical Systems - Comercial (PPO)
  • Independent Medical Systems - Seguro de accidentes laborales
  • Injury Management Organization - Seguro de accidentes laborales
  • Interlink - Red de trasplantes
  • LifeTrac - Red de trasplantes
  • Medicaid (Tradicional) - Medicaid/Medicare
  • Molina Healthcare - CHIP/CHIP Perinatal
  • Molina Healthcare - Comercial (Exchange)
  • Molina Healthcare - Medicaid (STAR, STAR Kids, STAR PLUS)
  • Molina Healthcare - Medicare Advantage
  • Molina Healthcare - Planes de doble elegibilidad para Medicare y Medicaid
  • MultiPlan - Comercial (Todos los productos)
  • OptumHealth - Red de trasplantes
  • Point Comfort Underwriters - Asistencia médica para refugiados (adultos, niños)
  • Private Healthcare Systems - Comercial (Todos los productos)
  • ProCare Advantage - Medicare Advantage (Plan para necesidades especiales)
  • Provider Partners Health Plan - Medicare Advantage (Plan para necesidades especiales)
  • Sales Claims Management - Seguro de accidentes laborales
  • SCAN Health - Medicare Advantage (Todos los productos)
  • Superior HealthPlan - CHIP/CHIP Perinatal
  • Superior HealthPlan - Medicaid (STAR, STAR Health Foster Care, STAR Kids, STAR PLUS)
  • Superior HealthPlan - Planes de doble elegibilidad para Medicare y Medicaid
  • Surest (United Healthcare) - Comercial (Todos los productos)
  • Tokio Marine - Red de trasplantes
  • TriWest - Región Oeste de TRICARE
  • TriWest - Red de atención comunitaria VA
  • Trustmark Benefits (antes CoreSource) - Administrador externo
  • UnitedHealthcare - Comercial (Charter EPO/HMO/POS)
  • UnitedHealthcare - Comercial (Choice Plus POS/PPO/Choice Plus-HAS)
  • UnitedHealthcare - Comercial (Compass EPO/HMO/POS)
  • UnitedHealthcare - Comercial (Core y Core Choice Plus EPO/HMO)
  • UnitedHealthcare - Comercial (Doctors Plan EPO/HMO/POS)
  • UnitedHealthcare - Comercial (Heritage EPO/HMO/POS)
  • UnitedHealthcare - Comercial (Indemnity)
  • UnitedHealthcare - Comercial (Navigate EPO/HMO/POS)
  • UnitedHealthcare - Comercial (Nexus ACO/EPO/HMO/POS)
  • UnitedHealthcare - Comercial (PPO)
  • UnitedHealthcare - Comercial (Select EPO/HMO/POS)
  • UnitedHealthcare - Comercial (Select Plus EPO/HMO/POS)
  • UnitedHealthcare - Medicare Advantage (Planes AARP, Planes Complete Care, Planes Erickson Advantage)
  • UnitedHealthcare - Medicare Advantage (Planes UnitedHealthcare Group, WellMed)
  • UnitedHealthcare Community Plan - CHIP/CHIP Perinatal
  • UnitedHealthcare Community Plan - Medicaid (STAR, STAR Kids, STAR PLUS)
  • UnitedHealthcare Community Plan - Planes de doble elegibilidad para Medicare y Medicaid
  • Universal Benefits Consortium (Allegiance) - Contrato directo con TPA/corredor para ISD seleccionados
  • University of Incarnate Word - Contacto directo con el empleador
  • Velocity National Provider Network - Comercial (Múltiples pagadores)
  • Velocity National Provider Network - Comercial (PPO)
  • Veterans Administration - Gubernamental
  • WellCare - Medicare Advantage
  • WellCare by Allwell (Medicare Advantage - Todos los productos)
  • WellCare by Superior HealthPlan - Dual Align (HMO D-SNP)
  • WellMed (Gonzaba Medical Group IPA) - Medicare Advantage (Solo trasplantes)
  • WellMed - Medicare Advantage (Cigna HealthSpring, Humana, United Healthcare, WellPoint)
  • WellPoint (Gonzaba) - Medicare Advantage (SOLO TRASPLANTES)
  • WellPoint - CHIP/CHIP Perinatal
  • WellPoint - Medicaid (STAR, STAR Kids, STAR PLUS)
  • WellPoint - Medicare Advantage (Todos los productos)
  • WellPoint - Medicare Advantage (Solo trasplantes)
  • WellPoint - Medicare Advantage (WellMed)
  • WellPoint - Planes de doble elegibilidad para Medicare y Medicaid
Please contact your health insurance company to confirm provider participation. For billing and insurance questions, please call our Billing Department at 210-358-3260.

Capítulos de libros

  1. Reau N, Poordad F. Primary Liver Cancer, Hepatocellular Carcinoma. Edited by Reau N and Poordad F. 2012 Humana Press.
  2. Poordad FF. Clinics in Liver Disease, A New Era in Hepatitis C. Edited by Poordad, F. 2011.
  3. Chee GM, Poordad FF. Hbv therapy following unsuccessful interferon therapy: how do you see the role for oral therapies? Clinical Dilemmas in Viral Liver Disease, 1st Edition, 2010, Blackwell Publishing.
  4. Poordad F, Chee GM. Pharmacology and mechanisms of action of antiviral drugs: Ribavirin analogues. Advanced Therapy for Hepatitis C Infection. 2010, Wiley-Blackwell.
  5. Poordad FF. Chronic Hepatitis C Infection: Factors Promoting Progression of Disease. Schiff’s Diseases of The Liver, 9th Edition.
  6. Poordad FF. Evaluation of Abnormal Liver Enzymes and the Role of Liver Biopsy. Advanced Therapy of Gastroenterology and Liver Disease, 5th Edition.; 604-610.

Other Publications

  1. Lawitz EJ, Shevell DE, Tirucherai GS, Du S, Chen W, Kavita U, Coste A, Poordad F, Karsdal M, Nielson M, Goodman Z, Charles ED. BMS-986263 in patients with advanced hepatic fibrosis: 36-week results from a randomized, placebo-controlled phase 2 trial. Hepatology. 2022 Apr; 75(4): 912-923. doi: 10.1002/hep.32181. Epub 2021 Dec 13.
  2. Flamm SL, Brown K, Wadei HM, Brown RS Jr, Kugelmas M, Samaniego-Picota M, Burra P, Poordad F, Saab S. The current management of hepatorenal syndrome-acute kidney injury in the United States and the potential of terlipressin. Liver Transpl. 2021 Aug; 27(8): 1191-1202. doi: 10.1002/lt.26072.
  3. Wiles D, Weiland O, Yao B, Weilert F, Dufour JF, Gordon SC, Stoehr A, Brown A, Mauss S, Zhang Z, Pilot-Matias T, Rodrigues L Jr, Mensa FJ, Poordad F. Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection. J Hepatol. 2019 May;70(5): 1019-1023.
  4. Zeuzem S, Foster GR, Wang S, Asatryan A, Gane E, Feld JJ, Asselah T, Bourlière M, Ruane PJ, Wedemeyer H, Pol S, Flisiak R, Poordad F, Chuang WL, Stedman CA, Flamm S, Kwo P, Dore GJ, Sepulveda-Arzola G, Roberts SK, Soto-Malave R, Kaita K, Puoti M, Vierling J, Tam E, Vargas HE, Bruck R, Fuster F, Paik SW, Felizarta F, Kort J, Fu B, Liu R, Ng TI, Pilot-Matias T, Lin CW, Trinh R, Mensa FJ. Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. N Engl J Med. 2018 Jan 25;378(4):354-369.
  5. Lawitz E, Poordad F, Wells J, Hyland RH, Yang Y, Dvory-Sobol H, Stamm LM, Brainard DM, McHutchison JG, Landaverde C, Gutierrez J. Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in DAA-experienced patients with genotype 1 HCV. Hepatology. 2017 Feb 21. doi: 10.1002/hep.29130.
  6. Poordad F, Lawitz E, Gutierrez JA, Guerrero J, Speeg K, Swenson ES. An HCV-positive recipient of an HCV-positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirin. Clin Case Rep. 2017 Feb 3;5(4):371-375.
  7. Poordad F, Felizarta F, Asatryan A, Sulkowski MS, Reindollar RW, Landis CS, Gordon SC, Flamm SL, Fried MW, Bernstein DE, Lin CW, Liu R, Lovell SS, Ng TI, Kort J, Mensa FJ. Glecaprevir and Pibrentasvir for 12 Weeks for HCV Genotype 1 Infection and Prior Direct-acting Antiviral Treatment. Hepatology. 2017 Jan 27. doi: 10.1002/hep.29081. [Epub ahead of print].
  8. Kwo PY, Poordad F, Asatryan A, Wang S, Wyles DL, Hassanein T, Felizarta F, Sulkowski MS, Gane E, Maliakkal B, Overcash JS, Gordon SC, Muir AJ, Aguilar H, Agarwal K, Dore GJ, Lin CW, Liu R, Lovell SS, Ng TI, Kort J, Mensa FJ. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol. 2017 Apr 13. pii: S0168-8278(17)30211-8. doi: 10.1016/j.jhep.2017.03.039. [Epub ahead of print].
  9. Wyles D, Poordad F, Wang S, Alric L, Felizarta F, Kwo PY, Maliakkal B, Agarwal K, Hassanein T, Weilert F, Lee SS, Kort J, Lovell SS, Liu R, Lin CW, Pilot-Matias T, Krishnan P, Mensa FJ. Glecaprevir/Pibrentasvir for HCV Genotype 3 Patients with Cirrhosis and/or Prior Treatment Experience: A Partially Randomized Phase III Clinical Trial. Hepatology. 2017 Sep 19. doi: 10.1002/hep.29541. [Epub ahead of print].
  10. Poordad F, Pol S, Asatryan A, Buti M, Shaw D, Hézode C, Felizarta F, Reindollar RW, Gordon SC, Pianko S, Fried MW, Bernstein DE, Gallant J, Lin CW, Lei Y, Ng TI, Krishnan P, Kopecky-Bromberg S, Kort J, Mensa F. Glecaprevir/Pibrentasvir in Patients with HCV Genotype 1 or 4 and Prior Direct-acting Antiviral Treatment Failure. Hepatology. 2017 Nov 20. doi: 10.1002/hep.29671. [Epub ahead of print].
  11. Poordad F, Nelson DR, Feld JJ, Fried MW, Wedemeyer H, Larsen L, Cohen DE, Cohen E, Mobashery N, Tatsch F, Foster GR. Safety of the 2D/3D direct acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - a pooled analysis. J Hepatol. 2017 Jun 20. pii: S0168-8278(17)32083-4. doi: 10.1016/j.jhep.2017.06.011. [Epub ahead of print].
  12. Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, McPhee F, Hughes EA, Noviello S, Swenson ES. Daclatasvir With Sofosbuvir and Ribavirin for HCV Infection With Advanced Cirrhosis or Post-Liver Transplant Recurrence. Hepatology. 2016 Jan 11. doi: 10.1002/hep.28446. [Epub ahead of print].
  13. Poordad F. Diagnosis, Treatment, and Monitoring of Patients With Primary Biliary Cholangitis. Gastroenterol Hepatol (N Y). 2016 Sep;12(9):561-564.
  14. Poordad F, Landis CS, Asatryan A, Jackson DF, Ng TI, Fu B, Lin CW, Yao B, Kort J. High Antiviral Activity of NS5A Inhibitor ABT-530 With Paritaprevir/Ritonavir and Ribavirin Against Hepatitis C Virus Genotype 3 Infection. Liver Int. 2016 Jan 18. doi: 10.1111/liv.13067. [Epub ahead of print].
  15. Gane E, Poordad F, Wang S, Asatryan A, Kwo PY, Lalezari J, Wyles DL, Hassanein T, Aguilar H, Maliakkal B, Liu R, Lin CW, Ng TI, Kort J, Mensa FJ. High Efficacy of ABT-493 and ABT-530 in Patients with HCV Genotype 1 or 3 Infection and Compensated Cirrhosis. Gastroenterology. 2016. pii: S0016-5085(16)34816-8.
  16. Muir AJ, Poordad F, Lalezari J, Everson G, Dore GJ, Herring R, Sheikh A, Kwo P, Hézode C, Pockros PJ, Tran A, Yozviak J, Reau N, Ramji A, Stuart K, Thompson AJ, Vierling J, Freilich B, Cooper J, Ghesquiere W, Yang R, McPhee F, Hughes EA, Swenson ES, Yin PD. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA. 2015;313(17):1736-44.
  17. Chan HL, Chan CK, Hui AJ, Chan S, Poordad F, Chang TT, Mathurin P, Flaherty JF, Lin L, Corsa A, Gaggar A, Subramanian GM, McHutchison JG, Lee S, Gane EJ. Effects of Tenofovir Disoproxil Fumarate in Hepatitis B e Antigen-Positive Patients with Normal Levels of Alanine Aminotransferase and High Levels of Hepatitis B Virus DNA. Gastroenterology. 2015;148(1):263.
  18. Poordad F. Hepatitis C Therapy: Simple for the Patient, not so Simple for the Clinician. Clin Liver Dis. 2015;19(4):ix-x.
  19. Poordad F, Agarwal K, Younes Z, Cohen D, Xie W, Podsadecki T. Low Relapse Rate Leads to High Concordance of SVR12 with SVR24 After Treatment with ABT-450/r, Ombitasvir, Dasabuvir Plus Ribavirin in Subjects with Chronic HCV Genotype 1 Infection in the AVIATOR Study. Clin Infect Dis. Clin Infect Dis. 2015;60(4):608-10.
  20. Forns X, Poordad F, Pedrosa M, Berenguer M, Wedemeyer H, Ferenci P, Shiffman ML, Fried MW, Lovell S, Trinh R, Lopez-Talavera JC, Everson G. Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopenia and hypoalbuminemia. Liver Int. 2015;35(11):2358-62.
  21. Poordad FF. Presentation and complications associated with cirrhosis of the liver. Curr Med Res Opin. 2015:1-27.
  22. Lawitz E, Poordad F, Brainard DM, Hyland RH, An D, Dvory-Sobol H, Symonds WT, McHutchison JG, Membreno FE. Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis. Hepatology. 2015;61(3):769-75.
  23. Poordad F, Rustgi V, Brown RS Jr, Patel V, Kugelmas M, Regenstein F, Balart L, LaBrecque D, Brown K, Avila M, Biederman M, Freed G, Smith R, Bernstein M, Arnold H, Cahan J, Fink S, Katkov W, Massoumi H, Harrison S. The impact of an educational program on HCV patient outcomes using boceprevir in community practices (OPTIMAL trial). Therap Adv Gastroenterol. 2015;8(5):263-9.
  24. Poordad F. Treatment of Hepatitis C Virus Genotype 3 Infection. Gastroenterol Hepatol (N Y). 2015;11(10):715-7.
  25. Poordad F, Sievert W, Mollison L, Bennett M, Tse E, Bräu N, Levin J, Sepe T, Lee SS, Angus P, Conway B, Pol S, Boyer N, Bronowicki JP, Jacobson I, Muir AJ, Reddy KR, Tam E, Ortiz-Lasanta G, de Lédinghen V, Sulkowski M, Boparai N, McPhee F, Hughes E, Swenson ES, Yin PD. UNITY-1 Study Group. Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection. JAMA 2015;313(17):1728-35.
  26. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, Shiffman ML, Wedemeyer H, Berg T, Yoshida EM, Forns X, Lovell SS, Silva-Tillmann BD, Collins CA, Campbell AL, Podsadecki T, Bernstein B. ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis. N Engl J Med. 2014;370(21):1973-82.
  27. Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson DR, Zeuzem S, Everson GT, Kwo P, Foster GR, Sulkowski MS, Xie W, Pilot-Matias T, Liossis G, Larsen L, Khatri A, Podsadecki T, Bernstein B. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med. 2014;370(3):222-32.
  28. Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourlière M, Sulkowski MS, Wedemeyer H, Tam E, Desmond P, Jensen DM, Di Bisceglie AM, Varunok P, Hassanein T, Xiong J, Pilot-Matias T, Dasilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B. Retreatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin. N Engl J Med. 2014;370(17):1604-14.
  29. Manns M, Marcellin P, Poordad F, de Araujo ES, Buti M, Horsmans Y, Janczewska E, Villamil F, Scott J, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, De La Rosa G, Kalmeijer R, Sinha R, Beumont-Mauviel M. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomized, double-blind, placebo-controlled phase 3 trial. Lancet. 2014;384(9941):414-26.
  30. Lawitz E, Poordad FF, Pang P, Hyland R, Ding X, Mo H, Symonds W, McHutchison J, Membreno F. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomized, phase 2 trial. Lancet. 2014;383(9916):515-23.
  31. Sulkowski MS, Poordad F, Manns MP, Bronowicki JP, Reddy KR, Harrison SA, Afdhal NH, Sings HL, Pedicone LD, Koury KJ, Sniukiene V, Burroughs MH, Albrecht JK, Brass CA, Jacobson IM. Anemia during treatment with peginterferon alfa-2b/ribavirin and boceprevir. Analysis from the SPRINT-2 trial. Hepatology. 2013;57(3):974-84.
  32. Poordad F, Lawitz E, Reddy KR, Afdhal NH, Hézode C, Zeuzem S, Lee SS, Calleja JL, Brown RS Jr, Craxi A, Wedemeyer H, Nyberg L, Nelson D, Rossaro L, Balart L, Morgan T, Bacon BR, Flamm SL, Kowdley KV, Deng W, Koury KJ, Pedicone LD, Dutko FJ, Burroughs MH, Alves K, Wahl J, Brass CA, Albrecht JK, Sulkowski MS. Effects of Ribavirin Dose Reduction vs Erythropoietin for Boceprevir-Related Anemia in Patients with Chronic HCV Genotype 1 Infection-a Randomized Trial. Gastroenterology 2013;145(5):1035-1044.
  33. Poordad F, Lawitz E, Kowdley K, Cohen D, Podsacki T, Siggelkow S, Heckaman M, Larsen L, Menon R, Koev G, Tripathi R, Pilot-Matias T, Bernstein B. Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis C. N Engl J Med 2013;368:45-53.
  34. Lawitz E, Poordad F, Kowdley KV, Cohen DE, Podsadecki T, Siggelkow S, Larsen L, Menon R, Koev G, Tripathi R, Pilot-Matias T, Bernstein A. Phase 2a Trial of 12-Week Interferon-Free Therapy with Two Direct-Acting Antivirals (ABT-450/r, ABT-072) and Ribavirin in IL28B C/C Patients with Chronic Hepatitis C Genotype 1. J Hepatol. 2013;59(1):18-23.
  35. 6. Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS, Poynard T, Morgan TR, Molony C, Pedicone LD, Sings HL, Burroughs MH, Sniukiene V, Boparai N, Goteti VS, Brass CA, Albrecht JK, Bacon BR; SPRINT-2 and RESPOND-2 Investigators. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology. 2012;143(3):608-618.
  36. Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS, Poynard T, Morgan TR, Molony C, Pedicone LD, Sings HL, Burroughs MH, Sniukiene V, Boparai N, Goteti VS, Brass CA, Albrecht JK, Bacon BR. SPRINT-2 and RESPOND-2 Investigators. Gastroenterology. 2012;143(3):608-618.
  37. Poordad F; McCone J; Bacon B; Bruno S; Manns M; Sulkowski M; Jacobson I; Reddy R; Boparai N; Sniukien V; Brass C; Albrecht JK. Bronowicki JP for the Sprint 2 Investigators. Boceprevir with Peginterferon and Ribavirin for Chronic Hepatitis C. N Engl J Med. 2011;364:1195-1206.
  38. Poordad F, Theodore D, Sullivan J, Grotzinger K. Medical Resource Utilization and Healthcare Costs in Patients with Chronic Hepatitis C Viral Infection and Thrombocytopenia. J Med Econ. 2011;14(2):194-206.
  39. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, Adler M, Reesink HW, Martin M, Sankoh AJ, Adda N, Kauffman RS, George S, Wright CI, Poordad F; ILLUMINATE Study Team. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011;365(11): 1014-24.
  40. Muir AJ, Poordad FF, McHutchison JG, Shiffman ML, Berg T, Ferenci P, Heathcote EJ, Pawlotsky JM, Zeuzem S, Reesink HW, Dusheiko G, Martin EC, George S, Kauffman RS, Adda N. Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. Hepatology. 2011;54(5):1538-46.
  41. Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP . Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071-81..
  42. Poordad F, Lawitz E, Shiffman ML, Hassanein T, Muir AJ, Bacon BR, Heise J, Halliman D, Chun E, Hammond J. Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C. Hepatology. 2010;52(4):1208-15.
  43. Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourlière M, Sulkowski MS, Wedemeyer H, Tam E, Desmond P, Jensen DM, Di Bisceglie AM, Varunok P, Hassanein T, Xiong J, Pilot-Matias T, Dasilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B. Retreatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin. N Engl J Med. 2014;370(17):1604-14.
Call 210-567-5777 to request an appointment with this doctor.
Back to Search

Patient reviews

    Descargue nuestra aplicación móvil

    Acceda a información médica, obtenga indicaciones paso a paso para navegar dentro de University Hospital, encuentre un médico o una ubicación, y mucho más.
    Más información